Regeneron Pharmaceuticals, Inc. (REGN)

$982.29

+14.31

(+1.48%)▲

Market is closed - opens 7 PM, 20 May 2024
star icon

Regeneron Pharmaceuticals Inc is a biopharmaceutical company that develops and commercializes medicines for serious medical conditions.

Insights on Regeneron Pharmaceuticals, Inc.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 3.43B → 3.14B (in $), with an average decrease of 8.4% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 1.15B → 722.0M (in $), with an average decrease of 37.7% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 56.5% return, outperforming this stock by 25.1%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 231.2% return, outperforming this stock by 140.9%

Performance

  • $966.00
    $982.77
    $982.29
    downward going graph

    1.66%

    Downside

    Day's Volatility :1.71%

    Upside

    0.05%

    downward going graph
  • $684.81
    $998.33
    $982.29
    downward going graph

    30.28%

    Downside

    52 Weeks Volatility :31.4%

    Upside

    1.61%

    downward going graph

Returns

PeriodRegeneron Pharmaceuticals, Inc.Sector (Health Care)Index (NASDAQ Composite)
3 Months
3.74%
0.5%
5.8%
6 Months
22.54%
14.1%
18.1%
1 Year
31.41%
11.9%
31.5%
3 Years
90.29%
18.7%
25.4%

Highlights

Market Capitalization
106.7B
Book Value
$250.15
Earnings Per Share (EPS)
33.88
PE Ratio
28.57
PEG Ratio
1.46
Wall Street Target Price
1057.62
Profit Margin
29.45%
Operating Margin TTM
24.12%
Return On Assets TTM
7.74%
Return On Equity TTM
15.28%
Revenue TTM
13.1B
Revenue Per Share TTM
122.57
Quarterly Revenue Growth YOY
-0.5%
Gross Profit TTM
7.0B
EBITDA
4.4B
Diluted Eps TTM
33.88
Quarterly Earnings Growth YOY
-0.13
EPS Estimate Current Year
44.2
EPS Estimate Next Year
47.87
EPS Estimate Current Quarter
10.09
EPS Estimate Next Quarter
10.89

Analyst Recommendation

Buy
    75%Buy
    21%Hold
    3%Sell
Based on 33 Wall street analysts offering stock ratings for Regeneron Pharmaceuticals, Inc.(by analysts ranked 0 to 5 stars)
Based on 33 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
25
25
22
Hold
7
7
9
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 7.67%

Current $982.29
Target $1,057.62

Company Financials

FY18Y/Y Change
Revenue
6.7B
↑ 14.28%
Net Income
2.4B
↑ 103.95%
Net Profit Margin
36.42%
↑ 16.01%
FY19Y/Y Change
Revenue
7.9B
↑ 17.18%
Net Income
2.1B
↓ 13.44%
Net Profit Margin
26.91%
↓ 9.51%
FY20Y/Y Change
Revenue
8.5B
↑ 8.06%
Net Income
3.5B
↑ 66.05%
Net Profit Margin
41.35%
↑ 14.44%
FY21Y/Y Change
Revenue
16.1B
↑ 89.14%
Net Income
8.1B
↑ 129.86%
Net Profit Margin
50.25%
↑ 8.9%
FY22Y/Y Change
Revenue
12.2B
↓ 24.26%
Net Income
4.3B
↓ 46.28%
Net Profit Margin
35.64%
↓ 14.61%
FY23Y/Y Change
Revenue
13.1B
↑ 7.76%
Net Income
4.0B
↓ 8.87%
Net Profit Margin
30.14%
↓ 5.5%
Q4 FY22Q/Q Change
Revenue
3.4B
↑ 16.29%
Net Income
1.2B
↓ 9.01%
Net Profit Margin
35.06%
↓ 9.75%
Q1 FY23Q/Q Change
Revenue
3.2B
↓ 7.39%
Net Income
817.8M
↓ 31.68%
Net Profit Margin
25.86%
↓ 9.2%
Q2 FY23Q/Q Change
Revenue
3.2B
↓ 0.13%
Net Income
968.4M
↑ 18.42%
Net Profit Margin
30.66%
↑ 4.8%
Q3 FY23Q/Q Change
Revenue
3.4B
↑ 6.48%
Net Income
1.0B
↑ 4.07%
Net Profit Margin
29.97%
↓ 0.69%
Q4 FY23Q/Q Change
Revenue
3.4B
↑ 2.13%
Net Income
1.2B
↑ 15.06%
Net Profit Margin
33.77%
↑ 3.8%
Q1 FY24Q/Q Change
Revenue
3.1B
↓ 8.42%
Net Income
722.0M
↓ 37.74%
Net Profit Margin
22.96%
↓ 10.81%
FY18Y/Y Change
Total Assets
11.7B
↑ 33.89%
Total Liabilities
3.0B
↑ 13.62%
FY19Y/Y Change
Total Assets
14.8B
↑ 26.17%
Total Liabilities
3.7B
↑ 24.8%
FY20Y/Y Change
Total Assets
17.2B
↑ 15.93%
Total Liabilities
6.1B
↑ 65.2%
FY21Y/Y Change
Total Assets
25.4B
↑ 48.19%
Total Liabilities
6.7B
↑ 8.6%
FY22Y/Y Change
Total Assets
29.2B
↑ 14.86%
Total Liabilities
6.6B
↓ 1.73%
FY23Y/Y Change
Total Assets
33.1B
↑ 13.23%
Total Liabilities
7.1B
↑ 8.5%
Q4 FY22Q/Q Change
Total Assets
29.2B
↑ 5.55%
Total Liabilities
6.6B
↑ 4.99%
Q1 FY23Q/Q Change
Total Assets
30.1B
↑ 2.89%
Total Liabilities
6.6B
↑ 0.22%
Q2 FY23Q/Q Change
Total Assets
30.7B
↑ 1.99%
Total Liabilities
6.6B
↑ 1.14%
Q3 FY23Q/Q Change
Total Assets
32.2B
↑ 4.91%
Total Liabilities
7.3B
↑ 9.33%
Q4 FY23Q/Q Change
Total Assets
33.1B
↑ 2.85%
Total Liabilities
7.1B
↓ 2.09%
Q1 FY24Q/Q Change
Total Assets
34.4B
↑ 3.9%
Total Liabilities
7.4B
↑ 3.82%
FY18Y/Y Change
Operating Cash Flow
2.2B
↑ 67.94%
Investing Cash Flow
-1.5B
↑ 45.55%
Financing Cash Flow
-77.1M
↑ 215.98%
FY19Y/Y Change
Operating Cash Flow
2.4B
↑ 10.7%
Investing Cash Flow
-2.0B
↑ 38.61%
Financing Cash Flow
-252.1M
↑ 226.98%
FY20Y/Y Change
Operating Cash Flow
2.6B
↑ 7.74%
Investing Cash Flow
-70.6M
↓ 96.52%
Financing Cash Flow
-2.0B
↑ 681.63%
FY21Y/Y Change
Operating Cash Flow
7.1B
↑ 170.47%
Investing Cash Flow
-5.4B
↑ 7527.05%
Financing Cash Flow
-1.0B
↓ 48.96%
FY22Y/Y Change
Operating Cash Flow
5.0B
↓ 29.18%
Investing Cash Flow
-3.8B
↓ 29.72%
Financing Cash Flow
-1.0B
↑ 0.32%
Q4 FY22Q/Q Change
Operating Cash Flow
1.7B
↑ 173.48%
Investing Cash Flow
-1.9B
↓ 1066.04%
Financing Cash Flow
-247.6M
↓ 65.85%
Q1 FY23Q/Q Change
Operating Cash Flow
1.4B
↓ 20.48%
Investing Cash Flow
-235.7M
↓ 87.31%
Financing Cash Flow
-322.5M
↑ 30.25%
Q2 FY23Q/Q Change
Operating Cash Flow
1.0B
↓ 25.24%
Investing Cash Flow
-2.4B
↑ 912.69%
Financing Cash Flow
-614.2M
↑ 90.45%

Technicals Summary

Sell

Neutral

Buy

Regeneron Pharmaceuticals, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
9.88%
22.54%
31.41%
90.29%
224.65%
Moderna, Inc.
Moderna, Inc.
30.29%
68.31%
6.04%
-16.69%
488.05%
Novo Nordisk A/s
Novo Nordisk A/s
7.45%
27.32%
56.5%
231.22%
458.15%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
13.15%
24.76%
31.15%
107.42%
168.64%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
28.57
28.57
1.46
44.2
0.15
0.08
NA
250.15
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.04
-0.38
-0.16
NA
33.47
Novo Nordisk A/s
Novo Nordisk A/s
46.03
46.03
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.58
28.58
0.53
17.11
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$106.7B
224.65%
28.57
29.45%
Moderna, Inc.
Moderna, Inc.
Buy
$50.8B
488.05%
24.73
-115.82%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$593.5B
458.15%
46.03
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$113.7B
168.64%
28.58
39.46%

Institutional Holdings

  • FMR Inc

    9.36%

  • Vanguard Group Inc

    8.02%

  • BlackRock Inc

    7.83%

  • JPMorgan Chase & Co

    6.56%

  • Capital World Investors

    4.66%

  • State Street Corporation

    4.45%

Company Information

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.

Organization
Regeneron Pharmaceuticals, Inc.
Employees
13677
CEO
Dr. Leonard S. Schleifer M.D., Ph.D.
Industry
Health Technology

Discover More

FAQs